Skip to content

Study · In vitro (cell-free) · 2012

5 results

Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues.

Torsello A, Bresciani E, Ravelli M, Rizzi L, Bulgarelli I, Ricci G, Ghiazza B, Del Puppo M, Mainini V, Omeljaniuk RJ, Tamiazzo L, Mancia G, Magni F, Locatelli V

Pharmacological research23 Jun 2012Cited by 10 (Europe PMC)

PMID22732396 (opens in a new tab)DOI10.1016/j.phrs.2012.06.006 (opens in a new tab)PepBankPUB-22732396
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In vitro, GHRP‑6 significantly inhibited ACE activity.

    In plain wordsIn lab tests, GHRP‑6 reduced the activity of the enzyme ACE.

    Peptide
    GHRP-6
    Outcome
    DecreaseACE activity
    Study

    n: not reported in source

    in vitro
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a.
  2. 02LabIn vitro (cell-free)Activity measurement

    In vitro, hexarelin significantly inhibited ACE activity.

    In plain wordsIn lab tests, hexarelin reduced the activity of the enzyme ACE.

    Peptide
    Hexarelin
    Outcome
    DecreaseACE activity
    Study

    n: not reported in source

    in vitro
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a.
  3. 03LabIn vitro (cell-free)Activity measurement

    In vitro, hexarelin did not blunt the protective effect of ACE, which cleaves amyloid-beta and reduces its aggregation, whereas enalapril did.

    In plain wordsIn lab tests, hexarelin did not block the ability of ACE to break down amyloid-beta, unlike enalapril.

    Peptide
    Hexarelin
    Outcome
    No significant changeACE cleavage of amyloid-beta
    Study

    n: not reported in source

    in vitro
    Comparator
    Enalapril
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, this protective effect of ACE was blunted by enalapril but not hexarelin or EP80317.
    1 context sentence
    Summary · context
    ACE was capable of cleaving Aβin vitro, reducing its ability to aggregate in fibrillar Aβ.
  4. 04LabIn vitro (cell-free)Activity measurement

    In vitro, hexarelin did not inhibit the N-domain of ACE.

    In plain wordsIn lab tests, hexarelin did not block one part (the N-domain) of the enzyme ACE.

    Peptide
    Hexarelin
    Outcome
    No significant changeACE N-domain inhibition
    Study

    n: not reported in source

    in vitro
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hexarelin or EP80317 do not inhibit the N-domain of ACE
  5. 05LabIn vitro (cell-free)Activity measurement

    In lab assays, MK-0677 had significantly lower ACE-inhibiting efficacy than desacyl ghrelin, hexarelin, EP80317, and GHRP-6.

    In plain wordsIn lab tests, MK-0677 inhibited ACE less effectively than desacyl ghrelin, hexarelin, EP80317, and GHRP-6.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseACE inhibition
    Study

    n: not reported in source

    Comparator
    Desacyl ghrelin, hexarelin, EP80317, and GHRP-6
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Desacyl ghrelin, hexarelin, EP80317, and GHRP-6 all significantly inhibited ACE activity in vitro; by comparison, the efficacies of ghrelin and MK-0677 were significantly lower, suggesting that ACE-inhibiting activity is unrelated to ligand affinity to GHS-R1a.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.